PARPinhibiittoreilla

PARPinhibiittoreilla, or PARP inhibitors, are a class of drugs that target poly(ADP-ribose) polymerase (PARP) enzymes. PARP enzymes play a crucial role in DNA repair, particularly in the base excision repair (BER) pathway. PARP inhibitors work by interfering with the activity of PARP enzymes, leading to the accumulation of DNA damage and ultimately cell death. This effect is particularly pronounced in cancer cells, which have a higher dependence on PARP-mediated DNA repair compared to normal cells.

The first PARP inhibitor to be approved for clinical use is olaparib (trade name Lynparza). Olaparib is used in the treatment of certain types of breast cancer, ovarian cancer, and prostate cancer. It has also shown promise in the treatment of other cancers, such as pancreatic cancer and certain types of leukemia, through clinical trials. Olaparib works by inhibiting PARP1 and PARP2, two of the nine PARP enzymes in humans.

PARP inhibitors are typically used in combination with other therapies, such as chemotherapy or hormone therapy, to enhance their effectiveness. This approach is known as PARP inhibition combined with chemotherapy (PIC) or PARP inhibition combined with endocrine therapy (PIE). The combination of PARP inhibitors with other treatments can lead to improved outcomes and reduced side effects compared to chemotherapy alone.

While PARP inhibitors have shown promise in cancer treatment, they are not without side effects. Common side effects include fatigue, nausea, diarrhea, and hair loss. More serious side effects, such as bone marrow suppression and increased risk of infections, have also been reported. Therefore, close monitoring and management of these side effects are essential during treatment.

Research is ongoing to develop new PARP inhibitors and to better understand their mechanisms of action and potential applications in other diseases, such as neurodegenerative disorders and inflammatory conditions. The ongoing research aims to optimize the use of PARP inhibitors and to identify new targets for this class of drugs.